CAR-T and T Cell Related Publications

  1. Design of chimeric antigen receptors with integrated controllable transient functions Alexandre Juillerat, Alan Marechal, Jean-Marie Filhol, Julien Valton, Aymeric Duclert, Laurent Poirot & Philippe Duchateau
    Scientific Reports 6, Article number: 18950 (2016) doi:10.1038/srep18950
  2. Pegram, H.J., et al.
    IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia, 2014.
    PMID: 25005243
  3. Pegram, H.J., J.H. Park, and R.J. Brentjens
    ICD28z CARs and armored CARs. Cancer J, 2014. 20(2): p. 127-33.
    PMID: 24667958
  4. Davila, M.L., et al.
    Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 2014. 6(224): p. 224ra25.
    PMID: 24553386
  5. Davila, M.L., et al.
    Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol, 2014. 99(4): p. 361-71.
    PMID: 24311149
  6. Riddell, S.R., et al.
    Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J, 2014. 20(2): p. 141-4.
    PMID: 24667960
  7. Jensen, M.C. and S.R. Riddell.
    Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev, 2014. 257(1): p. 127-44.
    PMID: 24329794
  8. Sadelain, M., R. Brentjens, and I. Riviere.
    The basic principles of chimeric antigen receptor design. Cancer Discov, 2013. 3(4): p. 388-98.
    PMID: 23550147
  9. Davila, M.L., et al.
    CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One, 2013. 8(4): p. e61338.
    PMID: 23585892
  10. Brentjens, R.J., et al.
    CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med, 2013. 5(177): p. 177ra38.
    PMID: 23515080
  11. Davila, M.L., et al.
    How do CARs work? Early insights from recent clinical studies targeting CD19. Oncoimmunology, 2012. 1(9): p. 1577-1583.
    PMID: 23264903
  12. Wang, X., et al.
    Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother, 2012. 35(9): p. 689-701.
    PMID: 23090078
  13. Terakura, S., et al.
    Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood, 2012. 119(1): p. 72-82.
    PMID: 22031866
  14. Brentjens, R.J., et al.
    Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 2011. 118(18): p. 4817-28.
    PMID: 21849486
  15. Brentjens, R.J., et al.
    Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res, 2007. 13(18 Pt 1): p. 5426-35.
    PMID: 17855649
  16. Brentjens, R.J., et al.
    Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med, 2003. 9(3): p. 279-86.
    PMID: 12579196
  17. Stromnes, I.M., et al.
    Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev, 2014. 257(1): p. 145-64.
    PMID: 24329795
  18. Schmitt, T.M., et al.
    Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood, 2013. 122(3): p. 348-56.
    PMID: 23673862
  19. Chapuis, A.G., et al.
    Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med, 2013. 5(174): p. 174ra27.
    PMID: 23447018